Strategies for access to affordable hepatitis C testing and treatment in Asia
MetadataShow full item record
JournalCurrent Opinion in HIV and AIDS
AbstractWith increasing availability of generic direct-acting antivirals (DAAs) and associated price reductions, various governments, multilateral institutions, and donors have started providing testing and treatment for hepatitis C virus (HCV) infection. More data on the quality of these generic medicines and on cost-effectiveness of their use are becoming widely available. This review seeks to describe some of the treatment programs for HCV that are evolving in Cambodia, India, Indonesia, Malaysia, Myanmar, and Thailand.
- Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
- Authors: Grillon C, Krishtel PR, Mellouk O, Basenko A, Freeman J, Mendão L, Andrieux-Meyer I, Morin S
- Issue date: 2018 Apr
- Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals.
- Authors: Hill A, Tahat L, Mohammed MK, Tayyem RF, Khwairakpam G, Nath S, Freeman J, Benbitour I, Helmy S
- Issue date: 2018 Apr 1
- The hepatitis C treatment revolution: how to avoid Asia missing out.
- Authors: Walsh N, Durier N, Khwairakpam G, Sohn AH, Lo YR
- Issue date: 2015 Oct 1
- High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C.
- Authors: Hill A, Khwairakpam G, Wang J, Golovin S, Dragunova J, Smith R, Houghton-Price V, Korologou-Linden R, Nath S, Savage A, Jefferys G
- Issue date: 2017 Oct 1
- Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments.
- Authors: Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, Shah S, Mamun-Al-Mahtab, Abbas Z, Johnston J, Tanwandee T, Wallace J
- Issue date: 2016 Nov